EAST NORRITON, Pa.--(BUSINESS WIRE)--The US District Court has ruled in favor of TGaS® Advisors in a recent lawsuit, denying a motion by Zensights for a preliminary injunction. As anticipated by TGaS Advisors, the Court decision cleared the way for TGaS to continue building on its TGaS Vendor Insights offering designed to serve its biopharmaceutical clients and vendors. The formal launch of this division is a continuation of the many years of providing biopharmaceutical clients information and ratings about vendors who support their business functions.
Among the US District Court’s findings, announced on August 1, were that TGaS undertook “its own, independent development of [a vendor solution].” The court further concluded that the preliminary injunction was not warranted and would stifle legitimate competition, adding that “Zensights failed to demonstrate that the TGaS product is actually a derivative of the Zensights product.”
TGaS Advisors’ CEO Stephen Gerard stated, “We are deeply gratified by the court’s across-the-board ruling in our favor. TGaS has always operated at the highest levels of confidentiality and ethical behavior. Our customers trust us with their most sensitive information, and we work tirelessly to continue to earn that trust.”
TGaS Vendor Insights provides the biopharmaceutical industry with a comprehensive set of listings and peer ratings for vendors (consultants, ad agencies, software and data providers and others) across business functions with vendor profiles, commentary and additional information.
About TGaS Advisors
TGaS Advisors is the leading benchmarking and advisory services firm for commercial organizations in the life sciences industry. With a roster of top 50, emerging and precommercial life sciences companies, TGaS provides robust comparative intelligence and collaborative network membership services. The team includes more than 60 experienced professionals, most with senior-level experience in the life sciences and related industries.